Enveric Biosciences, Inc.

https://enveric.com

Enveric Biosciences, Inc. is a biotechnology company dedicated to the discovery and development of novel neuroplastogenic small-molecule therapeutics. The company's core mission is to address significant unmet needs in psychiatric and neurological disorders, including depression, anxiety, and addiction. Headquartered in Cambridge, Massachusetts, Enveric focuses on creating innovative treatments for mental health conditions.

Enveric's primary pipeline candidate is EB-003, a novel neuroplastogen designed to promote neuroplasticity without inducing hallucinogenic effects, targeting difficult-to-treat mental health disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD). The company also develops the EVM401 series, which includes novel phenylalkylamines, indolethylamines, and mescaline-derived compounds aimed at treating addiction and various neuropsychiatric conditions like opioid withdrawal and ADHD. These drug candidates are derived from its proprietary discovery platform, The Psybrary™, a robust library of novel molecules.

Joseph Tucker, Ph.D., serves as the CEO and Director of Enveric Biosciences. In September 2025, the company relocated its corporate headquarters to Cambridge, Massachusetts, to foster collaborations and enhance visibility within the life sciences sector. Enveric has recently made significant progress, including receiving a favorable FDA response in September 2025 regarding its pre-Investigational New Drug (IND) meeting for EB-003, streamlining its path toward an IND submission expected in early 2026. The company also completed key manufacturing milestones for EB-003 in October 2025 and secured new U.S. patents for its EVM301 and EVM401 series in late 2025 and early 2026. As an early-stage biotechnology firm, Enveric is currently pre-revenue, with its valuation tied to its intellectual property and pipeline development.

Latest updates

Enveric to Highlight Non-Hallucinogenic Neuroplasticity Approach at Needham Forum

Event summary

  • Enveric Biosciences CEO Joseph Tucker, Ph.D., will participate in a panel discussion at Needham’s Virtual Psychedelics Forum on April 27, 2026.
  • The panel’s focus is on psychedelic therapies beyond treatment-resistant depression (TRD), specifically exploring non-hallucinogenic approaches and new indications.
  • Enveric’s management team will also conduct one-on-one meetings with investors and potential partners during the forum.
  • Enveric’s lead candidate, EB-003, is designed to engage both 5-HT₂A and 5-HT₁B receptors without hallucinogenic effects.

The big picture

The psychedelics sector is increasingly focused on therapies that avoid the hallucinogenic effects associated with traditional compounds, aiming for broader patient acceptance and regulatory approval. Enveric’s positioning as a developer of non-hallucinogenic neuroplastogenic therapeutics aligns with this trend, but the company faces the challenge of demonstrating clinical efficacy and securing regulatory clearance in a rapidly evolving market. Needham’s forum provides a platform for Enveric to articulate its strategy and attract investment in this competitive landscape.

What we're watching

Clinical Progress
The success of EB-003 hinges on demonstrating efficacy and safety in clinical trials, and the forum provides an opportunity to gauge investor confidence in the development timeline.
Partnering Activity
Enveric’s stated goal of securing partnerships suggests a potential need for external funding or expertise to advance its pipeline, and the forum’s investor meetings will be a key indicator of progress.
Regulatory Landscape
The FDA’s evolving stance on psychedelic therapies, particularly non-hallucinogenic compounds, will significantly influence Enveric’s path to commercialization, and any signals from the forum regarding regulatory engagement should be noted.

Enveric Biosciences Secures $13.9 Million Private Placement

Event summary

  • Enveric Biosciences closed a private placement of 2,222,223 shares (or pre-funded warrants) priced at $2.25 per share.
  • The gross proceeds from the offering were approximately $5 million, with potential additional proceeds of $8.9 million from warrant exercises.
  • H.C. Wainwright & Co. acted as the exclusive placement agent.
  • The warrants have exercise prices of $2.00 and expire 5 years after the Resale Registration Statement or 18 months thereafter.
  • Proceeds will be used for product development, working capital, and general corporate purposes.

The big picture

The at-the-market offering suggests Enveric is seeking capital to support its neuroplastogenic therapeutic development program, likely ahead of a larger financing round or potential partnership. The structure, including warrants, indicates a desire to minimize immediate dilution while providing upside potential for investors. The relatively small size of the raise, however, highlights the ongoing challenges in securing funding for early-stage biotech companies, particularly those focused on complex neurological disorders.

What we're watching

Warrant Exercise
The potential $8.9 million from warrant exercises represents a significant contingent liability and hinges on Enveric’s ability to generate investor confidence and achieve milestones that drive the stock price above the exercise price.
Resale Registration
The timeline for the Resale Registration Statement filing and its subsequent approval will dictate when and how the existing investors can liquidate their holdings, potentially impacting Enveric’s stock price and capital structure.
Cash Runway
Given the relatively modest $5 million raised, Enveric’s ability to extend its cash runway and fund its development pipeline will be heavily reliant on achieving key clinical or regulatory milestones and potentially securing further financing.

Enveric Bolsters Neuroplastogen Patent Portfolio with New U.S. Issuance

Event summary

  • Enveric Biosciences received U.S. Patent No. 12,577,232 on March 17, 2026, covering its EVM301 series of molecules.
  • The patent claims chemical compounds, formulations, and treatment methods for neurological disorders, building on existing patent No. 12,338,231.
  • EVM301 series includes EB-003, a lead candidate for mental health disorders, designed as a 5-HT2A / 5-HT1B dual-acting compound.
  • Enveric holds 27 issued U.S. patents and approximately 60 pending international applications related to its neuroplastogenic compounds.

The big picture

The patent strengthens Enveric’s position in a crowded neurotherapeutic market, where novel approaches to treating psychiatric disorders are increasingly sought after. Neuroplastogenic therapies represent a potential paradigm shift from traditional antidepressants, but face significant clinical and regulatory hurdles. This patent provides a degree of exclusivity, but the ultimate value will depend on clinical trial outcomes and market adoption.

What we're watching

Clinical Progress
The success of Enveric's planned IND application submission to the FDA and subsequent Phase 1 trial will be critical to validating the EVM301 series' potential and justifying the patent estate's value.
Competitive Landscape
How Enveric differentiates its neuroplastogenic approach from emerging competitors in the psychiatric and neurological disorder space will determine its long-term market position.
Patent Defense
The strength and defensibility of Enveric's patent portfolio, particularly given the complexity of tryptamine derivatives, will influence its ability to protect its intellectual property and maintain a competitive advantage.

Enveric Defends IP, Secures Funding Amidst Neuroplastogen Push

Event summary

  • Enveric Biosciences (ENVB) reported a net loss of $4.0 million for Q4 2025, and $12.2 million for the full year, raising $12.2 million through offerings.
  • The company completed a 1:12 reverse stock split on October 28, 2025.
  • A Post-Grant Review petition against Enveric’s patents, filed by Gilgamesh Pharmaceuticals and backed by AbbVie, was withdrawn.
  • Enveric secured FDA feedback allowing for a streamlined IND submission for its lead candidate, EB-003, targeting mental health disorders.

The big picture

Enveric’s focus on neuroplastogenic therapies addresses a significant unmet need in mental health, a market ripe for innovation given the limitations of existing treatments. The withdrawn PGR highlights the strategic importance of Enveric’s IP in a competitive landscape, while the recent funding rounds suggest ongoing investor interest despite the company’s current losses. The company's success will depend on translating preclinical data into clinical efficacy and securing sufficient capital to advance its pipeline.

What we're watching

Clinical Execution
The success of Enveric hinges on a timely and positive IND submission and subsequent Phase 1 trial for EB-003; delays or setbacks could significantly impact valuation.
IP Defense
While the withdrawal of the PGR was a win, future challenges to Enveric’s IP portfolio remain a risk, potentially impacting the commercial viability of its pipeline.
Funding Runway
With a current cash balance of $4.7 million, Enveric will need to secure additional funding to support clinical development, and the terms of that funding will be critical to maintaining shareholder value.

AbbVie Withdraws Patent Challenge Against Enveric, Signaling Confidence in Bretisilocin

Event summary

  • Enveric Biosciences’ patent (US 12,138,276) covering halogenated psilocybin derivatives, relevant to its bretisilocin (GM-2505) drug candidate, was the subject of a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals.
  • AbbVie acquired Gilgamesh Pharmaceuticals and its bretisilocin asset for up to $1.2 billion on August 12, 2025, making Gilgamesh a wholly-owned subsidiary of AbbVie.
  • Enveric retained Fish and Richardson P.C. to contest the PGR petition, filing a Request for Discretionary Denial.
  • AbbVie, through its subsidiary, formally requested the withdrawal of the PGR petition, which the USPTO granted on November 20, 2025.
  • The withdrawal effectively ends all current challenges to Enveric’s patent.

The big picture

The withdrawal of the patent challenge by AbbVie, now the owner of Gilgamesh, highlights the increasing scrutiny and legal battles surrounding intellectual property in the psychedelic-assisted therapy and neuroplasticity space. The $1.2 billion acquisition price for bretisilocin underscores the significant commercial potential of these therapies, but also the intense competition to secure patent protection. This event suggests AbbVie sees value in the underlying technology, even if it initially questioned the patent’s validity.

What we're watching

Deal Implications
AbbVie’s decision to withdraw the patent challenge suggests a level of comfort with Enveric’s intellectual property, but the underlying rationale for the initial challenge warrants further investigation – was it a strategic delaying tactic or a genuine concern about patent validity?
Clinical Progress
The success of bretisilocin’s clinical trials remains paramount; any setbacks could undermine the value of the acquired asset and potentially re-open questions about the patent’s strength.
Patent Landscape
While this challenge is resolved, Enveric's broader patent portfolio and its ability to defend it against future challenges will be critical to maintaining a competitive advantage in the emerging neuroplastogenic therapeutics space.

Enveric Data Highlights 5-HT₂A Signaling Pathway Separation

Event summary

  • Enveric Biosciences reported data showing its lead candidate, EB-003, activates both Gq- and β-arrestin-mediated signaling pathways downstream of the 5-HT₂A receptor.
  • The company developed proprietary BRET assays to characterize EB-003’s signaling profile, as existing commercial assays were inadequate.
  • Data indicate EB-003 exhibits a modest preference for β-arrestin signaling compared to serotonin.
  • A recent Nature study suggests that hallucinogenic effects are linked to Gi signaling, distinct from the antidepressant/anxiolytic effects mediated by Gq and β-arrestin.

The big picture

Enveric’s work underscores the growing understanding of nuanced receptor signaling pathways and the potential to develop targeted therapeutics with reduced side effects. The company's focus on non-hallucinogenic neuroplastogens represents a strategic shift away from traditional psychedelic approaches, aiming for broader patient accessibility and streamlined treatment protocols. The reliance on proprietary BRET assays highlights the challenges and opportunities in developing novel assays to characterize complex drug mechanisms.

What we're watching

Bias Specificity
The apparent β-arrestin signaling preference of EB-003 warrants close monitoring, as it could influence therapeutic efficacy and safety profiles, potentially impacting the clinical development pathway.
Regulatory Pathway
The FDA’s assessment of EB-003’s non-hallucinogenic profile will be crucial, as the separation of hallucinogenic and therapeutic effects could influence approval timelines and requirements.
Clinical Translation
The translation of preclinical BRET assay data into meaningful clinical outcomes will be a key determinant of EB-003’s ultimate success, requiring careful design and execution of Phase 1 and beyond trials.

Enveric Licenses RCANN Trademarks to TOTEC, Signals Asset Monetization

Event summary

  • Enveric Biosciences’ subsidiary, Akos Biosciences, licensed its US Trademark portfolio for RCANN™ to TOTEC Pharma.
  • TOTEC, an affiliate of Aries Science & Technology, is advancing the commercialization of cannabinoid crème technology originally developed by Enveric.
  • The trademark license includes an option for TOTEC to purchase the RCANN trademark portfolio based on future development and commercialization milestones.
  • The deal is intended to enhance the value of the previously licensed cannabinoid technology and support Enveric’s business development strategy.

The big picture

This trademark license and option agreement signals Enveric’s ongoing strategy of monetizing non-core assets to fund its primary focus on neuroplastogenic therapeutics. The deal with TOTEC, backed by Aries, highlights the growing interest in cannabinoid-based topical treatments, particularly for dermatological conditions like radiation dermatitis, a market with significant unmet need. The option structure suggests Enveric is seeking to retain upside potential while mitigating risk associated with TOTEC’s commercialization efforts.

What we're watching

Milestone Risk
The option to purchase the trademark portfolio is contingent on TOTEC achieving specific milestones, creating uncertainty around Enveric’s potential future revenue from the deal.
Commercialization
The success of TOTEC’s commercialization efforts for the cannabinoid crème will be critical in determining the overall value of the arrangement and potential royalties for Enveric.
Asset Strategy
Enveric’s continued focus on out-licensing non-core assets suggests a broader strategic shift towards concentrating resources on its neuroplastogenic therapeutics pipeline.

Enveric Biosciences Raises $1.5 Million via At-the-Market Offering

Event summary

  • Enveric Biosciences closed a registered direct offering of 328,802 common shares at $4.41 per share, raising approximately $1.5 million.
  • The offering included concurrent private placements of unregistered series G and H warrants, each exercisable for 328,802 shares at a $4.16 exercise price.
  • H.C. Wainwright & Co. served as the exclusive placement agent for the offering.
  • Proceeds will be used for product development, working capital, and general corporate purposes.
  • The offering was made under a 'shelf' registration statement declared effective by the SEC on April 17, 2025.

The big picture

This at-the-market offering provides Enveric Biosciences with a short-term funding boost, but the modest size and warrant structure highlight ongoing financial constraints. The company's success hinges on its ability to advance its neuroplastogenic therapeutics and demonstrate clinical efficacy, as the biotech sector faces increased scrutiny and funding challenges.

What we're watching

Capital Needs
The relatively small size of this offering ($1.5 million) suggests Enveric may be facing challenges in securing larger funding rounds, potentially impacting its development timeline.
Warrant Dynamics
The immediate exercisability of the series G warrants and the shorter expiration timeline for the series H warrants could create dilution risk if exercised, and the company's stock performance will influence their value.
Clinical Progress
The company's ability to demonstrate meaningful progress with its lead candidate, EB-003, will be crucial in attracting further investment and justifying the current valuation.

Enveric Biosciences Raises $1.5 Million via At-the-Market Offering

Event summary

  • Enveric Biosciences executed a registered direct offering of 328,802 common shares at $4.41 per share, raising approximately $1.5 million.
  • The offering includes concurrent private placements of unregistered warrants (Series G and H) exercisable at $4.16 per share.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent.
  • Proceeds will be used for product development, working capital, and general corporate purposes.
  • The offering is priced under Nasdaq rules and leverages a previously declared effective Form S-3 registration statement.

The big picture

Enveric’s decision to pursue an at-the-market offering, rather than a traditional institutional round, signals a potentially challenging fundraising environment for smaller biotech companies. The inclusion of warrants is a common tactic to incentivize participation in smaller offerings, but also introduces complexities regarding future dilution. The company’s ability to demonstrate progress in its neuroplastogenic drug development program will be paramount to maintaining investor confidence and securing future financing.

What we're watching

Capital Needs
The relatively small size of this offering ($1.5 million) suggests Enveric may be facing challenges in securing larger funding rounds, potentially impacting its development timeline.
Warrant Structure
The immediate exercisability of the warrants and their differing expiration timelines (5 years vs. 18 months) could create near-term dilution and influence share price volatility.
Pipeline Progress
The stated use of proceeds for product development will be critical; investors should monitor progress on EB-003 and other pipeline candidates to justify the financing.

Enveric Bolsters Neuropsychiatric Pipeline with New Patent

Event summary

  • Enveric Biosciences received U.S. Patent No. 12,492,179, covering ‘Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives’.
  • The patent claims compositions and methods of treatment for novel molecules targeting mental health disorders.
  • The patent expands Enveric’s intellectual property protection for neuroplastogenic molecules.
  • The molecules are based on existing compounds, chemically altered to potentially improve efficacy and reduce side effects.

The big picture

The patent issuance represents a strategic effort by Enveric to strengthen its intellectual property position in the competitive neuropsychiatric drug development space. Securing composition-of-matter patents is critical for attracting investment and potential partnerships, as it provides a stronger return-on-investment proposition for pharmaceutical companies. The focus on neuroplastogenic therapeutics reflects a broader trend towards novel approaches to treating mental health disorders, moving beyond traditional pharmacological interventions.

What we're watching

Clinical Trials
The success of Enveric's pipeline hinges on demonstrating clinical efficacy and safety of these novel molecules, and the timeline for IND filing and subsequent trials will be a key indicator of progress.
Partnerships
Given the complexity and cost of neuropsychiatric drug development, Enveric’s ability to secure licensing or partnership deals with larger pharmaceutical companies will be crucial for advancing its pipeline and recouping R&D investments.
Competitive Landscape
The neuropsychiatric drug market is crowded, and Enveric will need to demonstrate a clear advantage over existing therapies in terms of efficacy, safety, or convenience to gain market share.
CID: 609